Ridgefield Research and Innovation | Boehringer Ingelheim

Ridgefield, Conn. is home to Boehringer Ingelheim’s U.S. headquarters and one of the company’s leading research and development sites. The 330-acre site, which runs completely on renewable, hydro-electric energy, is conveniently located just one-hour drive from New York City. The site has more than 1,900 employees, including 800 Innovation Unit colleagues with expertise across research, development, and translational medicine and clinical pharmacology.

Consistently rated as a Global Top Employer and a top global pharmaceutical company, our mission is to discover and develop breakthrough therapies for patients. We prioritize investment in novel scientific concepts and first-in-class treatments in areas of high unmet patient needs.

Our dedicated scientists are doing just that. They’re tackling some of the most difficult challenges in healthcare and, together with our external research partners, they are working to accelerate the next breakthroughs that will transform patients’ lives – now and for generations to come.

“At the Ridgefield Innovation Unit, and in partnership with our global team of scientists, we foster creativity and put the patient at the center of our work. As an independent company, we have the freedom to follow our long-term vision – not the stock market – which allows us to lead the science and identify transformative treatments within and beyond our current research and development focus. Our scientific breakthroughs are a testament to this mindset.” – Dr. Carine Boustany, Senior Vice President, Site Head Discovery Research U.S. & Head of Global Immunology & Respiratory

“It’s easy to forget that our campus is within driving distance of both New York City and Boston. Like the renown academic centers around us – several of which we partner with – Boehringer Ingelheim conducts cutting edge research and development activities with the potential to improve the lives of patients around the world. Our talented scientists and leaders, together with our external partners, are continually creating value through innovation.” – Dr. Xiaorong He, Site Head Development U.S. and Global Head of Development Sciences

A woman smiling into the camera wearing glasses, a purple shirt and black blazer.

“Our Translational Medicine and Clinical Pharmacology team is collaborative and patient driven. Our biomarker team partners with our Research colleagues to build new therapeutic concepts into the right patient populations utilizing biomarker and imaging approaches. Our Clinical Pharmacology team works to characterize small and large molecule drugs in healthy volunteers and patients in early and late phase trials. This is in partnership with our Pharmacometrics team, who is responsible for modelling the pharmacokinetics and pharmacodynamics of these small and large molecule drugs to determine the appropriate doses to move forward in later phase clinical trials.” – Dr. Sudha Visvanathan, Vice President, Translational Medicine & Clinical Pharmacology (TMCP) Inflammation/TMCP U.S.